These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 29196440)

  • 41. Targeting cancer with kinase inhibitors.
    Gross S; Rahal R; Stransky N; Lengauer C; Hoeflich KP
    J Clin Invest; 2015 May; 125(5):1780-9. PubMed ID: 25932675
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cancer chemotherapy: a critical analysis of its 60 years of history.
    Galmarini D; Galmarini CM; Galmarini FC
    Crit Rev Oncol Hematol; 2012 Nov; 84(2):181-99. PubMed ID: 22542531
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
    Lee JY; Sun JM; Lim SH; Kim HS; Yoo KH; Jung KS; Song HN; Ku BM; Koh J; Bae YH; Lee SH; Ahn JS; Park K; Ahn MJ
    Clin Cancer Res; 2016 May; 22(9):2139-45. PubMed ID: 26667485
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment.
    Malka-Mahieu H; Newman M; Désaubry L; Robert C; Vagner S
    Clin Cancer Res; 2017 Jan; 23(1):21-25. PubMed ID: 27789529
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The choice of first-line chronic myelogenous leukemia treatment.
    Fava C; Rege-Cambrin G; Saglio G
    Ann Hematol; 2015 Apr; 94 Suppl 2(Suppl 2):S123-31. PubMed ID: 25814078
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Optimization of therapy. News in oncology and in management of infectious diseases].
    Chirurg; 1999 Jun; 70(6 Suppl):1-4. PubMed ID: 10416078
    [No Abstract]   [Full Text] [Related]  

  • 47. The confusion associated with breast cancer chemotherapy in Japan: the first year's experience at the Division of Oncology and Hematology, National Cancer Center Hospital East.
    Ohtsu T; Sasaki Y; Fujii H; Wakita H; Igarashi T; Itoh K; Imoto S; Abe K
    Jpn J Clin Oncol; 1995 Dec; 25(6):267-72. PubMed ID: 8523824
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular crosstalk between the proteasome, aggresomes and autophagy: translational potential and clinical implications.
    Driscoll JJ; Chowdhury RD
    Cancer Lett; 2012 Dec; 325(2):147-54. PubMed ID: 22781397
    [TBL] [Abstract][Full Text] [Related]  

  • 49. PARP inhibitors: A new era of targeted therapy.
    Tangutoori S; Baldwin P; Sridhar S
    Maturitas; 2015 May; 81(1):5-9. PubMed ID: 25708226
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Finding the right dose for cancer therapeutics--can we do better?
    Rubin EH; Anderson KM
    Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy.
    Austreid E; Lonning PE; Eikesdal HP
    Expert Opin Pharmacother; 2014 Apr; 15(5):681-700. PubMed ID: 24579888
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.
    Mignani S; Bryszewska M; Klajnert-Maculewicz B; Zablocka M; Majoral JP
    Biomacromolecules; 2015 Jan; 16(1):1-27. PubMed ID: 25426779
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Determinants of the recommended phase 2 dose of molecular targeted agents.
    Hansen AR; Cook N; Amir E; Siu LL; Abdul Razak AR
    Cancer; 2017 Apr; 123(8):1409-1415. PubMed ID: 28182250
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
    Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
    Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Servier's pipeline in oncology: moving from research to patients.
    Therasse P; Abastado JP
    Future Oncol; 2016 Mar; 12(5):589-94. PubMed ID: 26764971
    [No Abstract]   [Full Text] [Related]  

  • 56. PARP inhibitors in ovarian and other cancers.
    Plummer R
    Clin Adv Hematol Oncol; 2015 May; 13(5):285-7. PubMed ID: 26352770
    [No Abstract]   [Full Text] [Related]  

  • 57. The treatment of individual patients is more than a trial.
    Bottini A; Berruti A; Generali D; Dogliotti L
    J Natl Cancer Inst Monogr; 2011; 2011(43):53-4. PubMed ID: 22043040
    [No Abstract]   [Full Text] [Related]  

  • 58. [Future directions of anticancer drug development in Japan].
    Akaza H; Kawai K; Tsuruo T; Tsukagoshi S; Aiba K; Shimada Y; Kakeji Y; Ishikawa H; Ikeda T; Nakamura S; Tamura T; Yamamoto N; Isonishi S; Hinotsu S; Hirose M; Katsura J
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):351-60. PubMed ID: 18281781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Cytotoxic Agents and Immune Checkpoint Inhibitors].
    Kawazoe A; Shitara K
    Gan To Kagaku Ryoho; 2017 Sep; 44(9):717-721. PubMed ID: 28912395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
    Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.